Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

SE Sattui, JW Liew, K Kennedy, E Sirotich… - RMD open, 2021 - rmdopen.bmj.com
Background We describe the early experiences of adults with systemic rheumatic disease
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …

The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN …

R Talarico, S Aguilera, T Alexander… - Clinical and …, 2022 - sfera.unife.it
In order to address the main challenges related to the rare diseases (RDs) the European
Commission launched the European Reference Networks (ERNs), virtual networks involving …

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider …

J Liew, M Gianfrancesco, C Harrison, Z Izadi… - RMD open, 2022 - rmdopen.bmj.com
Objective While COVID-19 vaccination prevents severe infections, poor immunogenicity in
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …

Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.

C Tani, E Elefante, L Arnaud, SC Barreira… - Clinical and …, 2022 - europepmc.org
Objectives The purpose of this study was to review the frequency and clinical presentation of
the rarest clinical manifestations of systemic lupus erythematosus (SLE). Methods A list of 6 …

COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

M Putman, K Kennedy, E Sirotich, JW Liew… - The Lancet …, 2022 - thelancet.com
Before widespread vaccination programmes, potential side-effects and flares after COVID-
19 vaccination were frequent reasons for vaccine hesitancy among people with rheumatic …

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine …

M DiIorio, K Kennedy, JW Liew, MS Putman… - RMD open, 2022 - rmdopen.bmj.com
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28
days or longer, among people with systemic autoimmune rheumatic diseases (SARDs) …

Neuroinflammatory disease as an isolated manifestation of hemophagocytic lymphohistiocytosis

A Blincoe, M Heeg, PK Campbell, M Hines… - Journal of Clinical …, 2020 - Springer
Isolated neuroinflammatory disease has been described in case reports of familial
hemophagocytic lymphohistiocytosis (FHL), but the clinical spectrum of disease …

Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

JS Hausmann, K Kennedy, JF Simard… - The Lancet …, 2021 - thelancet.com
Background The impact and consequences of the COVID-19 pandemic on people with
rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance …

[PDF][PDF] ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody …

R Talarico, GA Ramirez, SC Barreira… - Clin. Exp …, 2023 - researchgate.net
Recent studies have shown that people who are immunocompromised may inadvertently
play a role in spurring the mutations of the virus that create new variants. This is because …

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the …

S Lawson-Tovey, PM Machado, A Strangfeld… - RMD open, 2022 - rmdopen.bmj.com
Background There is a lack of data on SARS-CoV-2 vaccination safety in children and
young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current …